STOCK TITAN

BCAX (NASDAQ: BCAX) insider plans stock sale after option exercise

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

BCAX insider Ryan Cohlhepp has filed a Form 144 notice to sell 3,828 shares of the company’s common stock through UBS Financial Services, Inc. on or about January 22, 2026 on the NASDAQ market. The planned sale has an aggregate market value of 64,961.16 based on the figures reported. These shares were acquired on May 12, 2024 by exercising a stock option from the issuer for cash.

The filing also lists prior sales of BCAX common stock by Cohlhepp during the past three months, including 12,500 shares sold on October 15, 2025 for gross proceeds of 226,942.50 and additional 12,500-share blocks in November and December 2025, plus a smaller sale on January 15, 2026. The notice includes a representation that the seller is not aware of undisclosed material adverse information about the issuer.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the BCAX Form 144 filing disclose?

The Form 144 discloses that Ryan Cohlhepp intends to sell 3,828 shares of BCAX common stock, with an aggregate market value of 64,961.16, through a broker on or about January 22, 2026.

How were the 3,828 BCAX shares being sold acquired?

The 3,828 common shares to be sold were acquired on May 12, 2024 via an exercise of stock options from the issuer, paid for in cash.

Which broker and exchange are involved in the BCAX Form 144 sale?

The planned sale will be executed through UBS Financial Services, Inc., located at Eleven Madison Avenue, New York, and the shares are listed for sale on the NASDAQ exchange.

What BCAX share sales has Ryan Cohlhepp made in the past 3 months?

The filing reports several prior sales of BCAX common stock by Ryan Cohlhepp over the past three months, including 12,500 shares sold on October 15, 2025 for 226,942.50, plus additional 12,500-share transactions in November and December 2025 and a sale of 149 shares on January 15, 2026.

What representation does the seller make in this BCAX Form 144?

By signing the notice, the person for whose account the securities are to be sold represents that they do not know any material adverse information about BCAX’s current or prospective operations that has not been publicly disclosed.

What is the reported number of BCAX shares outstanding in the Form 144?

The Form 144 indicates that there are 54,781,950 shares of BCAX common stock outstanding, providing context for the size of the planned sale.

Bicara Therapeutics

NASDAQ:BCAX

BCAX Rankings

BCAX Latest News

BCAX Latest SEC Filings

BCAX Stock Data

963.61M
45.05M
12.23%
93.98%
9.88%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON